Osteopenia Wearable Device Advertised Nationally
A new television campaign targets bone health for Americans over 50, highlighting a wearable device for osteopenia.
Updated on Sept. 25, 2026 in Senior Health
Live Poll
Do you trust medical devices advertised directly on television as much as doctor-recommended treatments?
In September 2026, the manufacturer of Osteoboost launched a national television campaign to promote its prescription wearable device for osteopenia. The marketing push comes as millions of Americans look for new ways to manage bone density loss.
Why it matters
The campaign targets the estimated 60 million Americans living with osteopenia, a condition where bones are weaker than normal but not yet osteoporotic. With half of all women over 50 eventually experiencing a fracture, the ads reflect a broader interest in bone health and longevity.
The device is a prescription-based wearable designed to mitigate bone density loss through targeted vibration. While current market reach data indicates 15% of users access the device via website-integrated telehealth, comparative outcomes against traditional drug therapies remain under study.
The players
Osteoboost
A developer of prescription wearable technology designed to treat osteopenia through targeted vibration.
DirectAvenue
A media placement agency that managed the broadcast distribution for the national television advertising campaign.
The details
The device is designed to be worn around the waist for 30 minutes daily to stimulate the spine and hips. It uses localized vibration technology to encourage bone density maintenance, aiming to reduce the risk of fractures in users with thinning bones. The company uses an in-house production team and media placement by DirectAvenue for its television spots.
Timeline
The national television advertising campaign launched in September 2026.
The brand recorded its highest weekend sales volume in September 2026.
Health Landscape
This development follows the expansion of the FDA-cleared osteopenia wearable technology category in response to growing consumer interest in non-pharmacological bone health management. It marks a shift in how medical devices are marketed directly to patients who may not currently use traditional prescription drugs.
If you are concerned about your bone density, discuss whether a non-pharmacological wearable device is an appropriate part of your treatment plan with your physician. Remember that roughly 10% of osteoporosis patients currently use pharmaceutical options, making a conversation about all available evidence-based interventions essential.
The takeaway
Effective management of osteopenia often requires a multifaceted approach to prevent future fractures. Talk to your doctor about your bone density scores and evaluate whether lifestyle modifications or medical interventions, such as prescription wearables, align with your specific health risks.
Further reading
Learn more about maintaining bone strength as you age in our Senior Health section.
More information
For more information on the device specifications and access, visit the Osteoboost product information and purchase site.
Source note: This article includes information reported by MediaPost.
Live Poll
Do you trust medical devices advertised directly on television as much as doctor-recommended treatments?
